Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (406)	1/24/2001 11:06:40 AM
From: tuck	Respond to of 1784

Trickle news implying DGEN, using ABSC technology, will compete with XGEN? biz.yahoo.com >>SAN DIEGO, Jan. 24 /PRNewswire/ -- Aurora Biosciences® Corporation (Nasdaq: ABSC - news) today announced that it has signed a non-exclusive license agreement with Deltagen, Inc. (Nasdaq: DGEN - news) for Aurora's proprietary green fluorescent protein (``GFP'') technology. Under the terms of the agreement, Deltagen was granted non-exclusive rights to use Aurora's GFP technology, one of Aurora's genomic platforms, in transgenic organisms, including knockout mice, within the United States. In consideration for such rights, Deltagen will make certain license fee payments to Aurora. In addition, Deltagen has the option to expand its use of Aurora's GFP technology into other territories upon additional payments to Aurora. Other financial terms were not disclosed. ``We are delighted that Deltagen has joined our licensing program to access Aurora's functional genomics technology,'' said Christopher W. Krueger, J.D., M.B.A., Aurora's vice president, strategic alliances and legal affairs. ``Deltagen's desire to use Aurora's GFP technology to discover in vivo mammalian gene function information and to determine the disease relevance of mammalian genes is another example of the widespread use of Aurora's GFP technology in drug discovery-related applications.'' ``As a leader in discovering new potential drug targets from genomic sequence, we are continually looking for leading-edge technologies to further our mission to commercialize the genome,'' said Bill Matthews, Ph.D., Deltagen's president and chief executive officer. ``Access to Aurora's GFP technology will augment our proprietary and Affymetrix-based technologies for studying the gene expression patterns in a living mammal. We are pleased to integrate Aurora's GFP technology into our drug target discovery platform.''<< snip Emphasis mine. Hmmmm. More digging to do. Cheers, Tuck